MBS, A., HO, H., & JMB, A. (2022). Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study. Computers in biology and medicine, 141, 105155. https://doi.org/10.1016/j.compbiomed.2021.105155
Chicago Style (17th ed.) CitationMBS, Al-Shuhaib, Hashim HO, and Al-Shuhaib JMB. "Epicatechin Is a Promising Novel Inhibitor of SARS-CoV-2 Entry by Disrupting Interactions Between Angiotensin-converting Enzyme Type 2 and the Viral Receptor Binding Domain: A Computational/simulation Study." Computers in Biology and Medicine 141 (2022): 105155. https://doi.org/10.1016/j.compbiomed.2021.105155.
MLA (9th ed.) CitationMBS, Al-Shuhaib, et al. "Epicatechin Is a Promising Novel Inhibitor of SARS-CoV-2 Entry by Disrupting Interactions Between Angiotensin-converting Enzyme Type 2 and the Viral Receptor Binding Domain: A Computational/simulation Study." Computers in Biology and Medicine, vol. 141, 2022, p. 105155, https://doi.org/10.1016/j.compbiomed.2021.105155.
